<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(1)</volume><submitter>Gorski D</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Tau protein aggregates are a key pathological hallmark of Alzheimer's disease (AD) and are closely associated with cognitive decline and neurodegeneration. It is proposed that tau aggregates faithfully propagate throughout the brain by self-templating their disease-associated conformation onto natively-folded tau monomers, thereby inducing their aggregation and incorporation into growing fibrils. As such, the inhibition or modulation of tau seeding and aggregation represents a viable therapeutic strategy for AD and other tauopathies.&lt;h4>Methods&lt;/h4>We have recently developed seed amplification assays (SAA) for the detection and amplification of small quantities of misfolded protein aggregates in various neurodegenerative diseases. In this article, we adapted the SAA tech</pubmed_abstract><journal>Alzheimer's research &amp; therapy</journal><pagination>214</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12482674</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Design and application of a Tau seed amplification assay for screening inhibitors of Tau seeding.</pubmed_title><pmcid>PMC12482674</pmcid><pubmed_authors>Mendez N</pubmed_authors><pubmed_authors>Banerjee V</pubmed_authors><pubmed_authors>Folke J</pubmed_authors><pubmed_authors>Evans H</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Allison T</pubmed_authors><pubmed_authors>Soto C</pubmed_authors><pubmed_authors>Barria C</pubmed_authors><pubmed_authors>Harrison D</pubmed_authors><pubmed_authors>Kaalund S</pubmed_authors><pubmed_authors>Aznar S</pubmed_authors><pubmed_authors>Shahnawaz M</pubmed_authors><pubmed_authors>Gorski D</pubmed_authors><pubmed_authors>Schultz P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Design and application of a Tau seed amplification assay for screening inhibitors of Tau seeding.</name><description>&lt;h4>Background&lt;/h4>Tau protein aggregates are a key pathological hallmark of Alzheimer's disease (AD) and are closely associated with cognitive decline and neurodegeneration. It is proposed that tau aggregates faithfully propagate throughout the brain by self-templating their disease-associated conformation onto natively-folded tau monomers, thereby inducing their aggregation and incorporation into growing fibrils. As such, the inhibition or modulation of tau seeding and aggregation represents a viable therapeutic strategy for AD and other tauopathies.&lt;h4>Methods&lt;/h4>We have recently developed seed amplification assays (SAA) for the detection and amplification of small quantities of misfolded protein aggregates in various neurodegenerative diseases. In this article, we adapted the SAA tech</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-04T01:49:54.537Z</modification><creation>2026-05-04T03:14:06.665Z</creation></dates><accession>S-EPMC12482674</accession><cross_references><pubmed>41029842</pubmed><doi>10.1186/s13195-025-01855-y</doi></cross_references></HashMap>